dalbavancin Side Effects
Also known as: Dalvance
Analysis of 911 adverse event reports submitted to the FDA from 2014 to 2025.
Total Reports
911
Death-Related
20
2.2% of reports
Hospitalizations
207
22.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 20 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 14 |
| OFF LABEL USE | 3 |
| TREATMENT FAILURE | 3 |
| PYREXIA | 2 |
| CEREBROVASCULAR ACCIDENT | 1 |
| CHILLS | 1 |
| DRUG DOSE OMISSION | 1 |
| DRUG INEFFECTIVE | 1 |
| EMBOLISM | 1 |
| HAEMORRHAGE | 1 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 1 |
| NAUSEA | 1 |
| PERIPHERAL SWELLING | 1 |
| RASH | 1 |
| SEPSIS | 1 |
| SUDDEN DEATH | 1 |
Reactions in Hospitalization Reports
Top reactions in 207 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 25 |
| OFF LABEL USE | 25 |
| DYSPNOEA | 18 |
| PYREXIA | 15 |
| NAUSEA | 14 |
| HYPERSENSITIVITY | 13 |
| ACUTE KIDNEY INJURY | 12 |
| RASH | 12 |
| ANAPHYLACTIC REACTION | 11 |
| INFUSION RELATED REACTION | 11 |
| VOMITING | 11 |
| PAIN | 9 |
| PRURITUS | 9 |
| ERYTHEMA | 8 |
| CELLULITIS | 7 |
| CHILLS | 7 |
| HYPOTENSION | 7 |
| MUSCLE SPASMS | 7 |
| PERIPHERAL SWELLING | 7 |
| SEPSIS | 7 |
Nearby — Related Medications
What the FAERS Data Reveals About dalbavancin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 911 voluntary reports linked to dalbavancin and its brand equivalents (Dalvance), spanning 2014 through 2025. Of those, 20 (2.2%) listed death as an outcome and 207 (22.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 48% were female and 51% male; age distribution skews toward 45-64, with 164 reports in that bracket. The single most reported reaction is off label use with 138 submissions, followed by rash and back pain.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.